Symptoms of infusion-related reactions and other drug-related AEs, listed by frequency, experienced by 3 or more patients during infusion and within 24 hours after completion of infusion (N = 21)
| AE . | n . | % . |
|---|---|---|
| Patients with at least 1 AE | 18 | 86 |
| Hypotension* | 11 | 52 |
| Pyrexia | 10 | 48 |
| Nausea* | 9 | 43 |
| Vomiting* | 8 | 38 |
| Chills* | 6 | 29 |
| Asthenia | 6 | 29 |
| Flushing | 3 | 14 |
| Headache | 3 | 14 |
| Larynx irritation | 3 | 14 |
| AE . | n . | % . |
|---|---|---|
| Patients with at least 1 AE | 18 | 86 |
| Hypotension* | 11 | 52 |
| Pyrexia | 10 | 48 |
| Nausea* | 9 | 43 |
| Vomiting* | 8 | 38 |
| Chills* | 6 | 29 |
| Asthenia | 6 | 29 |
| Flushing | 3 | 14 |
| Headache | 3 | 14 |
| Larynx irritation | 3 | 14 |
One patient experienced grade 3 hypotension, nausea, vomiting, and dizziness that resulted in the dosage being modified. Other grade 3 events were observed in a mantle cell lymphoma patient who experienced tumor lysis syndrome; events included asthenia, chills, dyspnea, headache, hyperkalemia, hyperthermia, leukopenia, and thrombocytopenia. No grade 4 infusion-related events were observed.